These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34424048)

  • 1. Recent Emergence of Aztreonam-Avibactam Resistance in NDM and OXA-48 Carbapenemase-Producing Escherichia coli in Germany.
    Nordmann P; Yao Y; Falgenhauer L; Sadek M; Imirzalioglu C; Chakraborty T
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0109021. PubMed ID: 34424048
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of Aztreonam-Avibactam-Resistant NDM-5-Producing Escherichia coli in the Food Chain.
    Sadek M; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0088221. PubMed ID: 34125588
    [No Abstract]   [Full Text] [Related]  

  • 3. Activity of aztreonam/avibactam against metallo-β-lactamase-producing Enterobacterales from the UK: Impact of penicillin-binding protein-3 inserts and CMY-42 β-lactamase in Escherichia coli.
    Livermore DM; Mushtaq S; Vickers A; Woodford N
    Int J Antimicrob Agents; 2023 May; 61(5):106776. PubMed ID: 36893810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3.
    Alm RA; Johnstone MR; Lahiri SD
    J Antimicrob Chemother; 2015 May; 70(5):1420-8. PubMed ID: 25634992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam-Avibactam Combination Restores Susceptibility of Aztreonam in Dual-Carbapenemase-Producing Enterobacteriaceae.
    Chew KL; Tay MKL; Cheng B; Lin RTP; Octavia S; Teo JWP
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29760136
    [No Abstract]   [Full Text] [Related]  

  • 7. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli.
    Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
    Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
    Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae.
    Niu S; Wei J; Zou C; Chavda KD; Lv J; Zhang H; Du H; Tang YW; Pitout JDD; Bonomo RA; Kreiswirth BN; Chen L
    J Antimicrob Chemother; 2020 Mar; 75(3):559-565. PubMed ID: 31722380
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.
    Le Terrier C; Nordmann P; Sadek M; Poirel L
    J Antimicrob Chemother; 2023 May; 78(5):1191-1194. PubMed ID: 36921067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.
    Sader HS; Mendes RE; Pfaller MA; Shortridge D; Flamm RK; Castanheira M
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory activity of avibactam against selected β-lactamases expressed in an isogenic Escherichia coli strain.
    Giani T; Cannatelli A; Di Pilato V; Testa R; Nichols WW; Rossolini GM
    Diagn Microbiol Infect Dis; 2016 Sep; 86(1):83-5. PubMed ID: 27394638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested
    Zhang Y; Kashikar A; Brown CA; Denys G; Bush K
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
    Sadek M; Juhas M; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases.
    Papp-Wallace KM; Bajaksouzian S; Abdelhamed AM; Foster AN; Winkler ML; Gatta JA; Nichols WW; Testa R; Bonomo RA; Jacobs MR
    Diagn Microbiol Infect Dis; 2015 May; 82(1):65-9. PubMed ID: 25737290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
    Mendes RE; Doyle TB; Streit JM; Arhin FF; Sader HS; Castanheira M
    J Antimicrob Chemother; 2021 Oct; 76(11):2833-2838. PubMed ID: 34436603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic synergy testing of ceftazidime-avibactam with aztreonam in a university hospital having high number of metallobetalactamase producing bacteria.
    Sahu C; Pal S; Patel SS; Singh S; Gurjar M; Ghoshal U
    Infect Dis (Lond); 2020 Nov; 52(11):801-807. PubMed ID: 32628575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.